NASDAQ$EYPT
EyePoint Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
EyePoint Pharmaceuticals' Q2 2021 financial results were announced, highlighting a 136% increase in net product revenues compared to Q2 2020 and positive safety data from the EYP-1901 DAVIO trial.
EyePoint Pharmaceuticals reported a strong second quarter, marked by significant progress in the Phase 1 DAVIO trial for EYP-1901 and a substantial increase in net product revenue, driven by growing customer demand for DEXYCU and YUTIQ.
- Net product revenues increased by 136% to $8.7 million compared to Q2 2020.
- Positive 30-day safety data was reported for all cohorts in the DAVIO trial of EYP-1901 for wet AMD.
- Patient enrollment was completed in the Phase 1 clinical trial of EYP-1901.
- DEXYCU achieved an all-time high in unit demand, with approximately 10,900 units, a 404% increase from Q2 2020.
Headline financials
Revenue & EPS history
EyePoint Pharmaceuticals · Revenue · Quarterly
$9.01M
Revenue by segment
EyePoint Pharmaceuticals · $9.01M total across 2 segments · Q2 2021
- Product sales, net$8.74M+135.8%96.9%
- License and Royalties$275K+685.7%3.1%
Forward guidance
EyePoint Pharmaceuticals expects its cash on hand and anticipated net cash inflows from product sales to fund current and planned operations through the end of 2022.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2021
-0.4%
Avg return
Earnings day
-1.2%
Avg return
5 days after
-3.7%
Avg return
30 days after
48%
28 / 58 earnings
Positive
+21.1%
Q3 2023
Best reaction
-37.2%
Q3 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.4% | +1.9% | -11.9% | |
| Q4 2025 | -1.9% | -14.5% | -26.9% | |
| Q3 2025 | -11.0% | -8.4% | +43.2% | |
| Q1 2025 | -2.2% | -6.4% | +43.0% | |
| Q4 2024 | +8.2% | +16.6% | -24.2% | |
| Q3 2024 | -3.7% | -8.0% | -27.9% | |
| Q2 2024 | +1.6% | -7.3% | -11.6% | |
| Q1 2024 | +6.7% | +2.9% | -23.3% | |
| Q4 2023 | -5.2% | -11.4% | -21.2% | |
| Q3 2023 | +21.1% | +26.7% | +9.8% | |
| Q2 2023 | -1.3% | -2.6% | -17.2% | |
| Q1 2023 | +4.5% | -0.3% | -7.9% | |
| Q4 2022 | +2.8% | -0.9% | -7.3% | |
| Q3 2022 | -1.3% | -3.5% | -37.5% | |
| Q2 2022 | +13.3% | +14.2% | -0.2% | |
| Q1 2022 | -4.9% | -19.5% | -23.8% | |
| Q4 2021 | +16.6% | +34.3% | +23.9% | |
| Q3 2021 | +10.1% | +26.1% | +18.6% | |
| Q2 2021 | +6.5% | +8.3% | +28.7% | |
| Q1 2021 | -8.1% | -14.8% | -12.0% | |
| Q4 2020 | -18.6% | -12.4% | -6.8% | |
| Q3 2020 | -7.5% | +10.0% | +30.0% | |
| Q2 2020 | -8.2% | -6.8% | -32.9% | |
| Q1 2020 | -3.3% | -2.2% | -8.9% | |
| Q4 2019 | -11.1% | -27.1% | -47.2% | |
| Q3 2019 | -37.2% | -41.6% | -35.1% | |
| Q2 2019 | +11.9% | +3.2% | +20.6% | |
| Q4 2018 | -3.5% | +2.2% | +41.0% | |
| Q3 2018 | +6.7% | -15.9% | -4.6% | |
| Q2 2018 | -2.7% | -5.5% | +12.7% | |
| Q1 2018 | -2.4% | +9.5% | +0.8% | |
| Q4 2017 | +1.6% | -5.5% | -3.1% | |
| Q3 2017 | +16.6% | +17.8% | +33.1% | |
| Q2 2017 | +4.1% | +5.3% | +0.0% | |
| Q1 2017 | +1.0% | -2.0% | -11.2% | |
| Q4 2016 | +1.6% | -4.1% | -35.7% | |
| Q3 2016 | +0.7% | — | — | |
| Q2 2016 | -10.1% | — | — | |
| Q1 2016 | -2.3% | — | — | |
| Q4 2015 | -1.3% | — | — | |
| Q3 2015 | -12.3% | — | — | |
| Q2 2015 | +2.3% | — | — | |
| Q1 2015 | +1.1% | — | — | |
| Q4 2014 | -1.5% | — | — | |
| Q3 2014 | +2.2% | — | — | |
| Q2 2014 | +4.6% | — | — | |
| Q1 2014 | -0.4% | — | — | |
| Q4 2013 | +2.2% | — | — | |
| Q3 2013 | +0.0% | — | — | |
| Q3 2012 | +2.1% | — | — | |
| Q4 2010 | -0.6% | — | — | |
| Q4 2012 | +3.1% | — | — | |
| Q1 2012 | +0.9% | — | — | |
| Q4 2011 | -6.9% | — | — | |
| Q3 2011 | -5.5% | — | — | |
| Q1 2011 | +1.6% | — | — | |
| Q3 2010 | -1.7% | — | — | |
| Q1 2010 | -4.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro